Estrella Immunopharma (NASDAQ:ESLA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Estrella Immunopharma (NASDAQ:ESLA) from a sell rating to a hold rating in a research note published on Saturday.

Several other brokerages have also weighed in on ESLA. Weiss Ratings reissued a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Wednesday, January 28th. D. Boral Capital cut their price objective on shares of Estrella Immunopharma from $16.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Price Performance

NASDAQ ESLA opened at $1.09 on Friday. The stock has a market capitalization of $41.17 million, a P/E ratio of -3.21 and a beta of 0.55. The firm’s 50-day moving average is $1.46 and its two-hundred day moving average is $1.43. Estrella Immunopharma has a 12 month low of $0.73 and a 12 month high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.